EN DE
Watch Solara Active Pharma Sciences Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Solara Active Pharma Sciences Limited (SOLARA) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Solara Active Pharma Sciences Limited stock ₹145, price ₹636, that is 77.2% below the price, quality 33 out of 100. Rating: strongly overvalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE624Z01016

SA Solara Active Pharma Sciences Limited logo Some data Nov 11, 2026

Solara Active Pharma Sciences Limited

SOLARA · NSE

Far too expensive (fair value 77% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Generates free cash flow 
Last quarter vs. a year ago: revenue +33%, profit +43%. 
Thin margins · 2.4% net margin (TTM) 
Some data 
Fair value ₹144.87 · Strongly overvalued 
Quality 33/100 
Weak Growth (revenue 5y −3.0 %/yr in INR) 
Trails peers (3/13) 
Narrow moat 28/100
⚠ Dilution
Watch Solara Active Pharma Sciences Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹1,775 ₹297.85 Fair Value ₹144.87 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range ₹297.85 – ₹1,775 · fair‑value band ₹83.78 – ₹210.41 · the ₹635.65 price screens above the ₹144.87 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow Solara Active Pharma Sciences in your weekly email

Every Wednesday you see whether Solara Active Pharma Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally.

Show moreShow less

The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antifibrinolytics, antigout agent, antihelmintic, antihistamine, antihyperlipoproteinemic, antimycotic, antifungal, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antiulcer, antiulcerative, anxiolytic, aprepitant, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, immune-suppressant, loop diuretic, NSAIDs, anti-hyperkalaemia, nucleoside inhibitor, OAB treatment, phenylalanine reducer, phosphate binder, reversal of neuro-muscular blocking agent, skeletal muscle relaxant, and topical anti-infectives.

It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical development, impurity synthesis, and regulatory support. In addition, the company exports its products.

The company was formerly known as SSL Pharma Sciences Limited and changed its name to Solara Active Pharma Sciences Limited in March 2017. Solara Active Pharma Sciences Limited was incorporated in 2017 and is based in Chennai, India.

Stock analysis

Solara Active Pharma Sciences Limited (SOLARA) currently trades at ₹635.65, while our model-based Fair Value estimate is ₹144.87, 77% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of ₹175.53 per share, and 0 of the 13 models we run sit above the ₹635.65 price.

Bear case: the Earnings-Based group reads lowest at ₹54.24, and 13 of the 13 models stay below the price. Data coverage for this calculation is medium.

Scenario range: ₹83.78 (bear) to ₹210.41 (bull), the price of ₹635.65 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Solara Active Pharma Sciences Limited reported revenue of ₹13.7B in FY2026 versus ₹12.7B in FY2022, a compound +1.9%/yr. Reported net income was −₹74.1M in FY2026.

Key figures

Market cap ₹30.6B (≈ $324M) Small · P/E ratio 82.2 · P/S ratio 1.99 · EPS (TTM) ₹7.71 · Net margin 2.4% · Return on equity 2.7% · Return on assets (EBIT) 1.3% (5-year average) · Operating margin 12.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 16% below its 52-week high and 49% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −77%, SOLARA screens richer than that median.

Fair Value models

Bear ₹83.78 Fair Value ₹144.87 Bull ₹210.41
Price ₹635.65 · Downside -77.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹4.86 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF ₹71.37 ₹92.73 ₹116.04 82
Growth DCF ₹72.24 ₹91.65 ₹112.05 80
Owner Earnings ₹60.04 ₹78.51 ₹98.68 78
All 13 models by family
DCF Models
FCF DCF ₹71.37 ₹92.73 ₹116.04 82
Owner Earnings ₹60.04 ₹78.51 ₹98.68 78
5Y Revenue Exit ₹107.41 ₹170.43 ₹247.54 72
5Y EBITDA Exit ₹211.79 ₹353.41 ₹510.80 74
10Y Revenue Exit ₹85.77 ₹131.14 ₹186.12 67
10Y EBITDA Exit ₹141.93 ₹231.26 ₹340.43 68
Earnings-Based
EPV ₹47.60 ₹54.24 ₹59.55 74
Multiples
EV/EBIT ₹98.57 ₹175.53 ₹252.49 63
EV/EBITDA ₹275.50 ₹411.44 ₹547.38 66
EV/Revenue ₹32.47 ₹103.09 ₹173.72 49
Asset-Based
NCAV (Graham) ₹90.03 ₹120.64 ₹180.06 54
Growth DCF
Growth DCF ₹72.24 ₹91.65 ₹112.05 80
Economic Profit
ROIC Compounder ₹47.60 ₹54.24 ₹59.55 72

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 33/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 22
How much profit the company makes from its sales and capital
Quality Growth 33
Are margins and returns getting better?
Cashflow 15
Do the profits arrive as real cash?
Financial strength 45
Debt, balance sheet and risk of trouble
Investment 97
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 60
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 55
Distance to the 52-week high, does not count
New shares 4
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+6.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.0%
Start year 2021 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.4% (2021) → 6.4% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
more than +80 %
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.

SOLARA screens overvalued: fair value 77% below the price. Compare with Merck KGaA →

Compare Solara Active Pharma Sciences Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 3/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 33 · Bottom 25%
Fair Value upside −77.2% · Bottom 25%
Profitability
Return on equity (12 months) 2.7% · Below median
Return on assets −0.3% · Below median
Net margin (12 months) 2.4% · Below median
Operating margin (12 months) 12.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 33.1% · Top 25%
Balance sheet
Debt / equity 0.09× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 82.2× · Priciest 25%
P/B 2.44× · Pricier than median
P/S (12 months) 1.99× · Cheaper than median
Price / free cash flow (fiscal year) 344.2× · Priciest 25%
EV/EBITDA 13.6× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 19
FUTURE (revenue growth)100 · sector 29
PAST (return on equity)11 · sector 26
HEALTH (low debt)96 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $83.82 $113.53 +35% vs SOLARA
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.02 ¥53.04 +10% vs SOLARA
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,868 ₹1,983 +6% vs SOLARA
Haleon plc HLN $9.17 $8.47 −8% vs SOLARA
Merck KGaA MRK €149.70 €108.83 −27% vs SOLARA
Galderma Group GALD CHF 191.00 CHF 112.30 −41% vs SOLARA
Takeda Pharmaceutical Company TAK $21.43 $11.20 −48% vs SOLARA
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs SOLARA
Teva Pharmaceutical Industries Limited TEVA $44.50 $20.74 −53% vs SOLARA
Divi's Laboratories Limited DIVISLAB ₹11,080 ₹1,567 −86% vs SOLARA

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Solara Active Pharma Sciences Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Solara Active Pharma Sciences Limited Fair Value". https://www.fairvalue-calculator.com/stock/SOLARA

Frequently asked questions

Is Solara Active Pharma Sciences Limited (SOLARA) overvalued or undervalued?
As of Nov 11, 2026, our model estimates a fair value of ₹144.87 versus a price of ₹635.65, about 77% lower (overvalued).
What is the fair value of SOLARA?
Our model-based fair value for Solara Active Pharma Sciences Limited is ₹144.87 (as of Nov 11, 2026), built from audited fundamentals. The current price: ₹635.65.
What is the quality score of SOLARA?
Solara Active Pharma Sciences Limited has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Solara Active Pharma Sciences Limited (SOLARA)?
Our model-based price target is the fair value of ₹144.87 (as of Nov 11, 2026) from 13 valuation models. Cautious scenario ₹83.78, optimistic scenario ₹210.41. It is a calculation from audited fundamentals, not an analyst target.
What is the Solara Active Pharma Sciences Limited stock forecast for 2026?
Our models put fair value at ₹144.87, about 77% lower versus a price of ₹635.65 (overvalued). Cautious scenario ₹83.78, optimistic scenario ₹210.41. The calculation is refreshed regularly with new filings.
What is the revenue of Solara Active Pharma Sciences Limited (SOLARA)?
Solara Active Pharma Sciences Limited reported trailing-twelve-month revenue of about ₹15.4B (latest available figure, as of Nov 11, 2026).
What growth is priced into Solara Active Pharma Sciences Limited (SOLARA)?
For today's price to be fair in a discounted-cash-flow model, Solara Active Pharma Sciences Limited would have to grow free cash flow by more than 80 % per year for five years (discount rate 13.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue fell 3.0 % per year. As of Nov 11, 2026.
What discount rate (WACC) does the fair value of SOLARA use?
Our models discount Solara Active Pharma Sciences Limited at 13.6 %: a base by market capitalisation (small), damped by beta 0.92, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Solara Active Pharma Sciences Limited that is more than 80 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.6 %) and the same formula as our fair value.
How much growth has Solara Active Pharma Sciences Limited (SOLARA) delivered so far?
Over the past 5 years revenue at Solara Active Pharma Sciences Limited shrank 3.0 % a year. The price currently implies free-cash-flow growth of more than 80 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Solara Active Pharma Sciences Limited (SOLARA) growing?
The median revenue growth in the sector is +7.3 % a year. That is the yardstick for the growth priced into Solara Active Pharma Sciences Limited (more than 80 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Solara Active Pharma Sciences Limited (SOLARA)?
The free-cash-flow yield on the price is 0.32 %: that much free cash flow Solara Active Pharma Sciences Limited produces per unit of market value. When it exceeds the discount rate of our models (13.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Solara Active Pharma Sciences Limited (SOLARA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Solara Active Pharma Sciences Limited it is ₹144.87 per share (as of Nov 11, 2026), against a price of ₹635.65. It is the blended result of 13 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is Solara Active Pharma Sciences Limited stock overvalued or undervalued in 2026?
As of Nov 11, 2026, SOLARA trades above its calculated fair value: price ₹635.65, fair value ₹144.87, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SOLARA?
No. The price is what the market pays today (₹635.65); the fair value is what the company's own numbers justify (₹144.87). For Solara Active Pharma Sciences Limited the two are ₹490.78 per share apart. That gap is exactly why we show both numbers side by side.
How much is Solara Active Pharma Sciences Limited worth?
The market values Solara Active Pharma Sciences Limited at about ₹30.6B (market capitalisation, as of Nov 11, 2026). Per share that is ₹635.65; our models calculate a fair value of ₹144.87 per share.
What do the bullish and bearish scenarios say about SOLARA?
Our models span a range for Solara Active Pharma Sciences Limited: cautious scenario ₹83.78, base ₹144.87, optimistic ₹210.41 per share (as of Nov 11, 2026, price ₹635.65). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SOLARA?
Solara Active Pharma Sciences Limited trades at a price-to-earnings ratio of 82.2 (as of Nov 11, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹144.87 is built from several models across several years. Other multiples: P/B 2.4, P/S 2.0, EV/EBITDA 13.6.
How solid is the balance sheet of Solara Active Pharma Sciences Limited (SOLARA)?
Balance-sheet figures for Solara Active Pharma Sciences Limited (as of Nov 11, 2026): return on equity 2.7%, debt of 0.09 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is SOLARA from its 52-week high?
Solara Active Pharma Sciences Limited trades at ₹635.65, about 16% below its 52-week high of ₹753.25 and 49% above the low of ₹425.55 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹144.87 is for.
Which stocks are comparable to Solara Active Pharma Sciences Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Solara Active Pharma Sciences Limited stock attractive at the current price?
The data as of Nov 11, 2026: price ₹635.65, calculated fair value ₹144.87 (−77%), Quality Score 33/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SOLARA calculated?
We run Solara Active Pharma Sciences Limited through 13 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of ₹144.87 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Solara Active Pharma Sciences Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Solara Active Pharma Sciences Limited (SOLARA)?
The closing price on Nov 16, 2026 was ₹635.65. Our model-based fair value is ₹144.87, about 77% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Solara Active Pharma Sciences Limited right now?
The price sits above even our optimistic bull case (₹210.41). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (₹83.78 to ₹210.41) leaves room in how you read the outcome.

Key figures of Solara Active Pharma Sciences Limited

How large is the market capitalisation of Solara Active Pharma Sciences Limited (SOLARA)?
The market capitalisation of Solara Active Pharma Sciences Limited is ₹30.6B (≈ $324M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Solara Active Pharma Sciences Limited (SOLARA)?
The price-to-sales ratio of Solara Active Pharma Sciences Limited is 1.99 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Solara Active Pharma Sciences Limited (SOLARA)?
Earnings per share at Solara Active Pharma Sciences Limited are ₹7.71 (price ÷ EPS = P/E 82.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Solara Active Pharma Sciences Limited (SOLARA)?
The net margin of Solara Active Pharma Sciences Limited is 2.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Solara Active Pharma Sciences Limited (SOLARA)?
The return on equity (ROE) of Solara Active Pharma Sciences Limited is 2.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Solara Active Pharma Sciences Limited (SOLARA)?
On an EBIT basis the return on assets of Solara Active Pharma Sciences Limited is 1.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Solara Active Pharma Sciences Limited (SOLARA)?
The operating margin of Solara Active Pharma Sciences Limited is 12.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Solara Active Pharma Sciences Limited (SOLARA)?
Revenue at Solara Active Pharma Sciences Limited is growing 33.1% versus a year earlier (3y avg −1.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Solara Active Pharma Sciences Limited (SOLARA)?
Earnings per share at Solara Active Pharma Sciences Limited are growing 43.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Solara Active Pharma Sciences Limited (SOLARA) carry?
The net debt of Solara Active Pharma Sciences Limited is ₹6.4B (fiscal year 2026, ≈ 71.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Solara Active Pharma Sciences Limited in the live analysis

One click puts Solara Active Pharma Sciences Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.